Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

UK Biotech, Edixomed, Develops Breakthrough Technology to Prevent and Treat Antibiotic Resistant Infection

Edixomed
Posted on: 20 Dec 17

19, December 2017, London, UK – New results announced at the recent Wounds UK conference and Eurobiofilms 2017 congress , have provided the latest evidence that Edixomed, a UK biotechnology company, has developed a revolutionary new technology for tackling the enormous public health challenge of antimicrobial resistance (AMR). Edixomed’s unique technology, which can be delivered as a liquid, gel or inhaled spray, rapidly and safely kills bacteria, viruses and fungi, including the hardest-to-treat antibiotic resistant strains.

 

“‘Super-bugs’, resistant to all currently available antibiotics, are expected to kill 10 million people a year by 2050. The threat is very real but we hope to soon have a viable and innovative solution with which to strike” said Professor Art Tucker, St Bartholomew's Hospital, London.

 

Through a novel mode-of-action, Edixomed’s core technology safely harnesses one of the body’s natural defence mechanisms, the nitric oxide cycle, to amplify the body’s own response in fighting infection, improving healing and potentially increasing the activity of any prescribed antibiotic. With decades of research supporting the potential of nitric oxide, Edixomed has developed a unique, safe and versatile system, with broad spectrum antimicrobial activity, and which can be used for a variety of clinical applications.

 

The latest data demonstrated that Edixomed’s breakthrough has the ability to kill all organisms for several deadly infections, such as MRSA and E. coli.1 Furthermore, Edixomed’s technology effectively prevented and treated multidrug-resistant bacteria biofilms – the large bacterial colonies with a protective layer which normally prevents the body’s immune system, or antibiotics, from being effective.2

 

“Here we have an innovative technology with multiple forms of delivery and applications. It can be inhaled into the lungs for respiratory conditions, applied to the skin as a gel or liquid, or used as a dressing for infected wounds or pre-surgical protection. With such broad applicability this truly could be the breakthrough we’ve been searching for in the fight against antibiotic resistance,” said Professor Ben Benjamin, Honorary Professor of Medicine of Exeter Medical School.

 

Edixomed’s nitric oxide technology is also being investigated in the clinic, with the most advanced developments in a UK-based randomised control study assessing safety and effectiveness in diabetic foot ulcers, the leading cause of diabetes related amputations.

 

Commenting on the substantial impact diabetic foot ulcers have, Dr Paul Chadwick, Clinical Director at the College of Podiatry, said, “treatment of diabetic foot ulcers currently costs the NHS more than £1 billion a year and infected ulcers lead to over 135 amputations per week. Early referral to foot-care services, reducing infection and accelerating healing, could significantly contribute to a reduction in the number of these avoidable amputations.”

 

There is also a compassionate use evaluation of Edixomed’s nitric oxide technology in Buruli ulcers in a clinic in Ghana. Buruli ulcer is one of the priority diseases recognised by the World Health Organization as a neglected tropical disease and most commonly occurs in children.  It is caused by a bacterial infection which can result in serious, chronic wounds, with the potential to cause significant scarring and deformity. Patients currently receive antibiotic therapy but it can be slow to work. An ability to tackle the infection more quickly would be a major breakthrough for these patients.

 

“We are excited by the results we have seen in the clinic and lab and we are working to maximise the potential benefit to as many patients as possible, and as quickly as possible. Edixomed has developed a completely new, important solution to the problem of antibiotic resistance,” said Professor Chris Wood, Chief Medical Officer, Edixomed.

 

About Edixomed

Edixomed is a biopharmaceutical company commercialising next generation and clinically-proven technologies from its nitric oxide platform. Using its patented and novel scientific approach, the company’s technologies are tackling major global health challenges in wound care, dermatology and infection control. The core technology’s unique feature is its ability to replenish or supplement the body’s own supply of nitric oxide that is critical for sustaining healthy skin and organs. Nitric oxide is depleted or absent in many diseases and, thus, the body’s normal healing and regenerative processes are damaged. Restoring that essential element is at the heart of Edixomed’s approach to innovative healthcare.

About nitric oxide

The discovery that a simple gas, nitric oxide (NO), could play such an important role in the human body led to three scientists being awarded the Nobel Prize in medicine. The pioneering work demonstrated that the normal function of NO is to control blood flow in the small vessels in the skin and prevent the skin from being infected with dangerous organisms. NO is also generated whenever the skin is injured or damaged and plays a crucial part in the normal skin healing process. However, in certain conditions, such as diabetes, the normal production of NO can be put at risk and the skin loses the essential ingredient it needs to repair itself. The result is a chronic, poorly healing wound, highly prone to infection and a major cause of concern to patients and doctors. Replenishing the missing NO in such a way as to mimic the skin’s natural production is no easy task and it has eluded many of the world’s leading scientists for the past two decades. Edixomed has succeeded in achieving this goal and has proven the performance of its technology in a large and robust clinical trial.

 

For further information please contact:

Martine Morris: Media Relations +44(0) 7939 801100 martinemorris@edixomed.com

Carl Daintree: Chief Operating Officer carldaintree@edixomed.com

You can also visit our website at: www.edixomed.com

 

References:

Sellars LE, et al. An assessment of the antimicrobial activity of a novel, nitric oxide generating wound treatment system according to the modified AATCC test method 100. Poster presentation at Wounds UK Annual Conference 2017.

Waite R, et al. Activity of nitric oxide generating dressing system against wound biofilms. Poster presentation at the 5th European Congress on Microbial Biofilms, Eurobiofilms 2017.

The World Health Organization. Neglected tropical diseases. Available at http://www.who.int/neglected_diseases/diseases/en/. Last accessed December 2017.

For more information:
www.edixomed.com

Editor's Details

Martine Morris
Edixomed
www.edixomed.com
+44(0) 7939 801100
martinemorris@edixomed.com

Last updated on: 20/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.